Tag: NICE

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document recommending Rinvoq (upadacitinib), from US drugmaker AbbVie (NYSE: ABBV), as a treatment of moderate to severe atopic dermatitis (AD) for adults and young people aged 12 and over, if the disease has not responded to at least […]